Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Benitec Biopharma Inc.NASDAQ: BNTC
Common Stock · Q3 FY2026 · quarter ended Mar 2026
Common stock rises 50.0% from a year ago
Common stock stood at $3K at the end of Q3 FY2026, up 50.0% from a year earlier and up 0.0% from the prior quarter.
Context
- Common stock amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +50.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 2K USD
- Year-over-year change
- +100.0%
- 4-year CAGR
- +18.9%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 2K | +100.0% |
| FY2024 | 2024-06-30 | 1K | — |
| FY2023 | 2023-06-30 | 0 | — |
| FY2022 | 2022-06-30 | 0 | -100.0% |
| FY2021 | 2021-06-30 | 1K | — |
Common Stock vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 common stock of $3K is the 9th highest of the 10 companies compared; the peer median is $89K.
- Its year-over-year change of +50.0% is the highest of 9, against a peer median of +5.7%.
- Common stock amounts to 0.0% of total assets for BNTC, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $529.66M | +8.2% | +5.4% | 483.6% | |
| Dec 2025 | $4.86M | +0.0% | -3.8% | 0.9% | |
| Mar 2026 | $3.38M | +15.8% | +12.1% | 5.9% | |
| Mar 2026 | $98K | +27.3% | +58.1% | 0.0% | |
| Mar 2026 | $89K | -1.1% | +1.1% | 0.0% | |
| Mar 2026 | $65K | +3.2% | +3.3% | 0.4% | |
| Mar 2026 | $22K | +22.2% | +16.3% | 0.0% | |
| Mar 2026 | $12K | +0.0% | +14.5% | 0.0% | |
| Mar 2026 | $3K | +50.0% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BNTC) | $89K | +5.7% | +8.8% | 0.0% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.